These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25063189)

  • 1. Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.
    Moreno JL; Palau Fayos JM; Díaz de Santiago A; García de Yébenes J
    J Huntingtons Dis; 2012; 1(1):31-2. PubMed ID: 25063189
    [No Abstract]   [Full Text] [Related]  

  • 2. Late-onset neuroleptic malignant syndrome in a patient using olanzapine.
    Kunz M; Gomes FA; Tramontina JF; Kapczinski F
    J Clin Psychopharmacol; 2007 Jun; 27(3):303-4. PubMed ID: 17502780
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa.
    Ayyıldız H; Turan Ş; Gülcü D; Poyraz CA; Pehlivanoğlu E; Çullu F; Arıkan MK
    Eat Weight Disord; 2016 Jun; 21(2):309-11. PubMed ID: 26607823
    [No Abstract]   [Full Text] [Related]  

  • 4. [Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone].
    López-Torres E; Cobo I; Lucena MI
    Actas Esp Psiquiatr; 2007; 35(2):145-6. PubMed ID: 17401786
    [No Abstract]   [Full Text] [Related]  

  • 5. [Electroconvulsion therapy for neuroleptic malignant syndrome].
    Buggenhout S; Vandenberghe J; Sienaert P
    Tijdschr Psychiatr; 2014; 56(9):612-5. PubMed ID: 25222100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olazapine induced neuroleptic malignant syndrome.
    Zaragoza Fernández M; Torres García E
    Actas Esp Psiquiatr; 2006; 34(2):144-5. PubMed ID: 16552643
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome with aripiprazole in Huntington's disease.
    Gahr M; Orth M; Abler B
    Mov Disord; 2010 Oct; 25(14):2475-6. PubMed ID: 20669301
    [No Abstract]   [Full Text] [Related]  

  • 8. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome.
    Tofler IT; Ahmed B
    J Clin Psychopharmacol; 2003 Dec; 23(6):672-4. PubMed ID: 14624203
    [No Abstract]   [Full Text] [Related]  

  • 9. Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment.
    Oglodek E; Szota A; Araszkiewicz A
    Aust N Z J Psychiatry; 2013 Oct; 47(10):972. PubMed ID: 23630396
    [No Abstract]   [Full Text] [Related]  

  • 10. Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.
    Margetic B; Aukst-Margetic B
    World J Biol Psychiatry; 2007; 8(2):131-2; author reply 133-4. PubMed ID: 17455107
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine induced neuroleptic malignant syndrome.
    Patra BN; Khandelwal SK; Sood M
    Indian J Pharmacol; 2013; 45(1):98-9. PubMed ID: 23543750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome.
    Mendhekar DN; Duggal HS
    J Neuropsychiatry Clin Neurosci; 2006; 18(4):552-3. PubMed ID: 17135384
    [No Abstract]   [Full Text] [Related]  

  • 13. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.
    Liu PY; Wu PC; Chen CY; Chen YC
    Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.
    Stevens DL; Lee MR; Padua Y
    Pharmacotherapy; 2008 Mar; 28(3):403-5. PubMed ID: 18294120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.
    Srivastava A; Borkar HA; Chandak S
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):119-21. PubMed ID: 19067992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine.
    Mishra B; Mishra B; Sahoo S; Arora M; Khess CR
    Indian J Med Sci; 2007 Oct; 61(10):570-3. PubMed ID: 17932448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.
    Musselman ME; Browning LA; Parker D; Saely S
    Ann Pharmacother; 2011 Nov; 45(11):e61. PubMed ID: 21972252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine-induced neuroleptic malignant syndrome with mental retardation.
    Margolese HC; Chouinard G
    Am J Psychiatry; 1999 Jul; 156(7):1115-6. PubMed ID: 10401467
    [No Abstract]   [Full Text] [Related]  

  • 19. Olanzapine and neuroleptic malignant syndrome.
    Tofler I
    Psychosomatics; 2002; 43(6):505-6; author reply 506. PubMed ID: 12444237
    [No Abstract]   [Full Text] [Related]  

  • 20. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.
    Ahuja N; Palanichamy N; Mackin P; Lloyd A
    J Psychopharmacol; 2010 Jan; 24(1):125-30. PubMed ID: 18801826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.